CA-CENTR
24.10.2023 15:01:33 CEST | Business Wire | Press release
Centr, a health and wellness ecosystem founded by Chris Hemsworth, today announced an all-new partnership with HYROX, the World Series of Fitness Racing, as its new Official Equipment Provider for all races. The partnership marks Centr’s initial entry into the competitive sports space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231023422267/en/
Beginning in 2024, HYROX races will feature newly designed, custom Centr competition equipment. The new performance line will feature battle ropes, power sleds, one-of-a-kind interlocking bumper weight plates with edge markings to indicate the weight being lifted, pushed, and pulled; 8-edged modified competition kettlebells for optimum grip support, aerodynamics, and weight distribution, as well as sandbags, wall balls and targets, racks and rigs.
“As a brand that is focused on making holistic wellness and fitness as accessible to as many as possible, the partnership with HYROX perfectly aligns with our ethos,” said Andrew Sugerman, CEO of Centr. “HYROX has created a highly regarded competitive fitness platform that is globally accessible, and we’re excited to work with them to bring our innovative approach to product design and premium digital content to their competitions and community.”
The Centr-HYROX competition products are designed with multiple environments in mind. In addition to HYROX competitions, the Centr equipment will be available to affiliate gyms, studios, and home gyms, allowing HYROX competitors the ability to train with the same equipment they will use on race day.
“We designed a competition format that would provide for the healthiest and most complete test of fitness that was accessible to the widest possible population of participants through the rigorous application of Sports Science Principles," said Christian Toetzke, Founder of HYROX. ”This process created a unique need for a range of ultra high quality, varied equipment that we needed to trust to provide a consistent experience for our community across training and competition. Centr has provided that product whilst instinctively understanding the soul of our sport.”
In line with the company’s mission of pairing physical tools with digital resources, Centr will also make its award-winning digital content available to HYROX competitors and develop a custom training program to support race day preparation. Centr’s digital coaching will also help motivate and support ongoing fitness, performance, and well-being beyond race day.
“Similar to Centr’s approach with our current members, we want to provide HYROX competitors with the same tools and resources to power their routines,” added Sugerman. “At Centr, we strive to inspire everyone to be the healthiest and happiest version of themselves with the balance of movement, meals and mind. Through our partnership with HYROX, we are also underscoring the importance of motivation to serve as a catalyst across Centr’s brand pillars and hope that this partnership gives them the tools, support, and community to realize their limitless potential.”
The new Centr equipment will make its debut at HYROX competitions in early 2024. For more information on the Centr x HYROX performance line and to get a preview of commercial equipment that will be made available for purchase, please visit https://join.centr.com/hyrox/.
About Centr
Centr is a leading fitness and wellness platform founded by Chris Hemsworth with a mission to empower people to live well by energizing their every day. Inspired by Chris Hemsworth’s team of experts, Centr offers personalized training and tips spanning movement, meals, and mind to fuel members’ daily healthy habits. To further help members achieve their health and fitness goals, Centr is expanding its platform to add transformational in-home fitness equipment and accessories, available at select retailers worldwide. To learn more, visit www.Centr.com.
About HYROX
HYROX is the Global Sport of Fitness Racing, inspiring people worldwide to engage in the healthiest form of training and competition on earth. HYROX connects the world’s training communities with a sport, a training methodology and a lifestyle that is accessible to all and conveys the transformative benefits of training and competition to a globally connected audience.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231023422267/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom